Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803734 | 1.00 | KLK7 (0.63) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL356995 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29397834 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29397799 | 0.97 | KLK7 (0.60) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL12606016 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL10983363 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL29401353 | 0.96 | KLK7 (0.59) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL18337922 | 0.92 | FOLH1 (0.56) | KLK7KLK5FOLH1CA1CA2 | |
| SCHEMBL9976419 | 0.92 | FOLH1 (0.56) | KLK7KLK5FOLH1CA1CA2 | |
| SCHEMBL8613001 | 0.89 | FOLH1 (0.52) | KLK7KLK5FOLH1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3153514-B1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | ICOS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-10710962-B2 | Zwitterionic reagents | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3153514-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9512073-B2 | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2121725-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | Novo Nordisk Health Care AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-2115001-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008107260-A1 | COUPLING OF ANTIBODY POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK A/S (DK) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008098958-A1 | C-TERMINAL ATTACHMENT OF TWO CHEMICAL GROUPS TO PEPTIDES | NOVO NORDISK HEALTH CARE AG (DK) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | KLK7 2695/4885KLK5 3402/4885MAPT 3874/4885 |
| US-10336756-B2 | (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | KLK7 2059/4885KLK5 2239/4885MAPT 4691/4885 |
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | KLK7 2081/4885KLK5 3299/4885MAPT 3944/4885 |
| US-10710962-B2 | Zwitterionic reagents | BTD, HLCS, WIZ | KLK7 2359/4885KLK5 2258/4885MAPT 2081/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | KLK7 2273/4885KLK5 3455/4885MAPT 4423/4885 |
| US-20210332047-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | KLK7 2273/4885KLK5 3455/4885MAPT 4423/4885 |
| US-10906907-B2 | Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof | PIK3CD, PIK3CA, PIK3CB | KLK7 2785/4885KLK5 3547/4885MAPT 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.